COVID-19 and Coronary Stent Thrombosis: A Systematic Review of Literature

Pramod Theetha Kariyanna¹, Amog Jayarangaiah², Sushruth Das², Apoorva Jayarangaiah³, Ashkan Tadayoni⁴, Moro O. Salifu⁴ and Isabel M. McFarlane^4,

¹Division of Interventional Cardiology, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Morningside/Beth Israel Hospitals, New York City, NY-10025, U.S.A.

²Trinity School of Medicine, 925 Woodstock Road, Roswell, GA 30075, U.S.A.

³Department of Internal Medicine, Albert Einstein College of medicine/ Jacobi Medical Center, Bronx, NY 10461, U.S.A

⁴Department of Internal Medicine, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, U.S.A.

Cite this paper:
Pramod Theetha Kariyanna, Amog Jayarangaiah, Sushruth Das, Apoorva Jayarangaiah, Ashkan Tadayoni, Moro O. Salifu and Isabel M. McFarlane. COVID-19 and Coronary Stent Thrombosis: A Systematic Review of Literature. American Journal of Medical Case Reports. 2021; 9(6):308-311. doi: 10.12691/ajmcr-9-6-1

Abstract

Coronavirus Disease-19 (COVID-19) is a worldwide pandemic and it has created many difficulties in providing medical care due to the various multi-organ disease manifestations caused by the virus. In this paper we explore cases of stent thrombosis which occurred in patients who were infected with COVID-19 and discuss its role in potentiating this complication through the variety of mechanisms in which it creates a prothrombotic state. Stent thrombosis is described as the thrombotic occlusion of a coronary stent. The incidence of this complication has decreased considerably (from 16% to 0.7%) since the advent of antiplatelet therapy and drug eluting stents. In this systematic review, 8 papers were found which detailed 11 patients who were infected with COVID-19 and suffered a stent thrombosis. Data from these cases were tabulated and analyzed. The ages of the patient’s ranged from 49-81 years and quite interestingly the time between the time of stent placement and occurrence of stent thrombosis had great variation between patients, with some occurring within minutes of stent placement and others occurring in a stent that was placed many years ago. 91% of the patients had ST-segment elevation myocardial infarction (STEMI) for presentation of stent thrombosis and 9% had a non-ST segment myocardial infarction (NSTEMI) on presentation. Therapy mainly involved antiplatelet therapy and Percutaneous Coronary Angioplasty with new stent placement. Despite this mortality rate among the cases present was quite high at 45%, with some patients dying as a result of COVID-19 related complications. Through various literature reviews, we have found that COVID-19 contributes in creating a prothrombotic state through various inflammatory mediated mechanisms. This prothrombotic state is a major risk factor towards stent thrombosis and we recommend that physicians be aware of this potentially fatal complication in COVID-19 patients.

Keywords:
COVID-19 coronary stent thrombosis antiplatelets percutaneous coronary intervention acute myocardial infarction

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Longobardo L, Mattesini A, Valente S, Di Mario C. OCT-guided Percutaneous Coronary Intervention in Bifurcation Lesions. Interv Cardiol. 2019 Feb; 14(1): 5-9.
[2]	Noaman S, O'Brien J, Andrianopoulos N, Brennan AL, Dinh D, Reid C, Sharma A, Chan W, Clark D, Stub D, Biswas S, Freeman M, Ajani A, Yip T, Duffy SJ, Oqueli E., Melbourne Interventional Group Investigators. Clinical outcomes following ST-elevation myocardial infarction secondary to stent thrombosis treated by percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020 Oct 01; 96(4): E406-E415.
[3]	Zhao XY, Li JX, Tang XF, Xu JJ, Song Y, Jiang L, Chen J, Song L, Gao LJ, Gao Z, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention: A Prospective Observational Study. Chin Med J (Engl). 2018 Nov 20; 131(22): 2699-2704.
[4]	Kim YH, Her AY, Jeong MH, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. A comparison of the impact of current smoking on 2-year major clinical outcomes of first- and second-generation drug-eluting stents in acute myocardial infarction: Data from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore). 2019 Mar; 98(10): e14797.
[5]	Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clinical and Applied Thrombosis/Hemostasis. January 2020.
[6]	Lacour T, Semaan C, Genet T, Ivanes F. Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients [published online ahead of print, 2020 Apr 30]. Catheter Cardiovasc Interv. 2020; 10.1002/ccd.28948.
[7]	Prieto-Lobato A, Ramos-Martínez R, Vallejo-Calcerrada N, Corbí-Pascual M, Córdoba-Soriano JG. A Case Series of Stent Thrombosis During the COVID-19 Pandemic. JACC Case Rep. 2020; 2(9): 1291-1296.
[8]	Choudhary R, Kaushik A, Sharma JB. COVID-19 pandemic and stent thrombosis in a post percutaneous coronary intervention patient-a case report highlighting the selection of P2Y12 inhibitor. Cardiovasc Diagn Ther. 2020; 10(4): 898-901.
[9]	Zaher N, Sattar Y, Mahmood S, Vacek T, Alraies MC. COVID-19 Infection Complicated by a Complete Occlusion of the Left Circumflex Artery With Acute Restenosis After Drug-Eluting Stent Placement. Cureus. 2020; 12(9): e10708. Published 2020 Sep 29.
[10]	Hinterseer, M., Zens, M., Wimmer, R.J. et al. Acute myocardial infarction due to coronary stent thrombosis in a symptomatic COVID-19 patient. Clin Res Cardiol (2020).
[11]	Mohamed Ayan, Swathi Kovelamudi & Malek Al-Hawwas (2021) Subacute stent thrombosis in a patient with COVID-19 pneumonia, Baylor University Medical Center Proceedings, 34: 1, 175-177.
[12]	Antuña P, Rivero F, del Val D, Cuesta J, Alfonso F. Late Coronary Stent Thrombosis in a Patient With Coronavirus Disease 2019. JAMA Cardiol. 2020; 5(10): 1195-1198.
[13]	Galeazzi GL, Loffi M, Di Tano G, Danzi GB. Severe COVID-19 Pneumonia and Very Late Stent Thrombosis: a Trigger or Innocent Bystander?. Korean Circ J. 2020 Jul; 50(7): 632-633.
[14]	Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020; 192: 152-160.
[15]	Kariyanna, Pramod Theetha, et al. 'Thrombus in Transit and Impending Pulmonary Embolism Detected on POCUS in a Patient with COVID-19 Pneumonia.' American Journal of Medical Case Reports 8.8 (2020): 225-228.
[16]	Merad, M., Martin, J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20, 355-362 (2020).
[17]	Swystun, Laura L., and Patricia C. Liaw. "The role of leukocytes in thrombosis." Blood, The Journal of the American Society of Hematology 128.6 (2016): 753-762.
[18]	Kashi M, Jacquin A, Dakhil B, et al. Severe arterial thrombosis associated with Covid-19 infection. Thromb Res. 2020; 192: 75-77.
[19]	Kariyanna PT, Sutarjono B, Grewal E, et al. A Systematic Review of COVID-19 and Myocarditis. Am J Med Case Rep. 2020; 8(9): 299-305.
[20]	Kariyanna PT, Hossain N, Jayarangaiah A, et al. Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report. Am J Med Case Rep. 2020; 8(7): 192-196.
[21]	Kariyanna PT, Chandrakumar HP, Jayarangaiah A, et al. Apical Takotsubo Cardiomyopathy in a COVID-19 Patient Presenting with Stroke: A Case Report and Pathophysiologic Insights. Am J Med Case Rep. 2020; 8(10): 350-357.